![]() To our knowledge, this is the first in-depth characterization of the problem of financial toxicity in this patient population. Therefore, to address this knowledge gap, we conducted a single institutional semistructured interview study with cancer patients enrolled in phase I clinical trials to assess the effects of financial toxicity from trial participation. ![]() 7 Moreover, the unique characteristics of early phase trials, such as their experimental nature, uncertain therapeutic outcomes, and the potential for serious adverse events, may contribute to heightened financial and psychosocial burdens. ![]() ![]() Understanding the financial implications of participating in phase I oncology trials is essential because these trials often involve more frequent and extensive evaluations, treatments, and follow-ups compared with standard care, potentially exacerbating financial toxicity. Thus, this paper aims to contribute to the body of knowledge concerning financial toxicity in early phase clinical trials, with a tailored focus on phase I clinical trials. 5, 6 However, few studies have particularly examined the financial toxicity experienced by cancer patients enrolled in early phase clinical trials. 4 Previous research has reported that cancer patients in the standard of care setting face substantial financial toxicity, with high out-of-pocket costs and financial distress often leading to treatment nonadherence and a decline in quality of life. 3įinancial toxicity is a multi-dimensional construct that encompasses direct costs (eg, medical bills), indirect costs (eg, lost wages), and psychosocial aspects (eg, anxiety and stress related to financial issues). However, participation in clinical trials can impose financial burdens on patients, their families, and the health care system, a phenomenon known as financial toxicity. ![]() 2 Participation in a clinical trial can be the best option for every cancer patient at any stage of their disease. 1 Patients with advanced cancer who have exhausted standard treatment options may choose to participate in these trials in the hope of benefiting from novel therapies. The development and evaluation of novel cancer therapies often involve early phase clinical trials, with phase I trials being crucial for determining the safety, tolerability, and appropriate dosing of investigational agents. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |